Aduro Biotech — J.P. Morgan Healthcare Conference 2017
31 slides from Aduro Biotech's conference presentation, Jan 9, 2017

Slide 1: Pioneering Immunotherapy. Transforming Lives.
J.P. Morgan Healthcare Conference January 2017 Pioneering Immunotherapy. Transforming Lives. Exhibit 99.1

Slide 2: Disclaimer: Special Note Regarding Forward-Looking Statements
Disclaimer Special Note Regarding Forward-Looking Statements This presentation and the accompanying oral presentation include express and implied forward-looking statements regarding the current intentions, expectations, estimates, opinions and beliefs of Aduro Biotech, Inc. (“Aduro”) that are not h

Slide 3: Aduro Highlights
Aduro Highlights Three distinct immunotherapy platforms Well-positioned for future of immuno-oncology using rational combinations Strategy to both partner assets and develop wholly-owned assets Strong cash and IP position LADD Novel, live, attenuated Listeria platform to stimulate tumor immunity Con

Slide 4: Aduro: Small Cap with Large Potential
Aduro: Small Cap with Large Potential 3 immunotherapy platforms 3 validating large pharma partnerships, one per platform 10+ pipeline candidates >10 indications 162 employees in U.S./Europe $387M in cash at Q3 2016 $2.3B value of upfront & milestones from existing partners (total potential value)

Slide 5: Notable 2016 Accomplishments
Notable 2016 Accomplishments Corporate achievements and notable news Steve Isaacs named 2016 Visionary Leader by Berkeley Chamber of Commerce Oncology expert and industry veteran Natalie Sacks, M.D. joined as Chief Medical Officer Hans van Eenennaam & John Dulos honored with award for contributions

Slide 6: Aduro's Place in Cancer Therapy
ADURO’S PORTFOLIO Aduro’s Place in Cancer Therapy Cancer Immunotherapy: Ushering in a new era in cancer treatment LADD pLADD Anti-PD1 Anti-CTLA4 Anti-APRIL Anti-CD27 Therapeutic vaccines Checkpoint Inhibitors Monoclonal Antibodies MOA APPROACHES OS CURVE* Chemotherapy Targeted therapy Immune checkpo

Slide 7: Comprehensive Immunotherapy Portfolio Empowers Rational Combination Strategy
Comprehensive Immunotherapy Portfolio Empowers Rational Combination Strategy Immune Agonists Checkpoint Inhibitors ROBUST POSITION IN IMMUNOTHERAPY uniquely positions Aduro for flexible combinations for more patients Chemo- therapy Radio- therapy Targeted Therapies Cellular Therapies Modulate Activa

Slide 8: Aduro's Development Pipeline
Program Indication Combination Discovery / Preclinical Phase 1 Phase 2 Phase 3 Partner LADD Programs CRS-207 2nd Line Mesothelioma αPD-1 CRS-207 Ovarian αPD-1/Epi CRS-207 Gastric αPD-1 ADU-741 Prostate ADU-214 Lung pLADD Gastro-intestinal STING Pathway Programs ADU-S100 Multiple Tumors ADU-S100 Mult

Slide 9: LADD
LADD

Slide 10: LADD Platform: Induces Robust Immune Response
LADD Platform: Induces Robust Immune Response Stimulates Innate Immunity Responses and Antigen-specific T Cell Responses Broad innate response (cytokines, chemokines, gamma delta T cells and NK cells) Antigen-specific adaptive T cell response (CD4+ and CD8 + T cells)

Slide 11: LADD Platform: Bacterial Vector to Induce Innate & Adaptive Immunity
LADD Platform: Bacterial Vector to Induce Innate & Adaptive Immunity Differentiated gene engineering for safety and efficacy Deletion of two virulence genes substantially reduces disease-causing properties Multivalent antigen cassettes for antigen expression Favorable safety profile in trials to dat

Slide 12: CRS-207: Mesothelioma Phase 1b
CRS-207: Mesothelioma Phase 1b, Cohort 1 Single-arm trial with CRS-207 + SOC chemotherapy (pemetrexed/cisplatin) Non-resectable malignant pleural mesothelioma patients with no prior treatment 94% Disease control rate for combo of CRS-207 & pemetrexed/cisplatin 31% Patients had tumor shrinkage with C

Slide 13: CRS-207: Mesothelioma Strategy
CRS-207: Mesothelioma Strategy Second-line presents attractive entry opportunity Unmet need No approved agents or standard of care Likely quicker data read out Pre-clinical synergy provides rationale for combination approach Chemotherapies DCR 43-59% and mPFS 2.8-4.9 months Checkpoints have DCR of 5

Slide 14: Janssen Partnership: Lung and Prostate Cancers
Janssen Partnership: Lung and Prostate Cancers Lung Cancer: ADU-214/JNJ-64041757 Encouraging initial results in ongoing Phase 1 study Patients with advanced (stage IIIb) or metastatic (stage IV) NSCLC Evidence of mesothelin-specific T cell responses If data remain consistent, Janssen will advance in

Slide 15: Personalized LADD (pLADD)
Personalized LADD (pLADD) LADD vector well-suited to maximize the potential of personalized therapy Induces an innate immune response and tumor-specific T cell-mediated immunity Allows for engineering of multiple tumor-specific neoantigens Efficient small-scale manufacturing process capability pLADD

Slide 16: STING
STING

Slide 17: ADU-S100: Activates Innate & Adaptive Immunity
ADU-S100: Activates Innate & Adaptive Immunity Intratumoral injection of ADU-S100 leads to an “inflamed” tumor phenotype Stimulates priming of CD8+ T cells specific for any individual’s unique tumor antigens in preclinical models

Slide 18: STING Platform: Off-the-Shelf Patient-Specific Therapy
STING Platform: Off-the-Shelf Patient-Specific Therapy Family of proprietary small molecules Synthetic compounds are more potent than natural STING ligands ADU-S100, lead product candidate, in Phase 1 clinical trial Ongoing dose-escalation trial Significant anti-tumor activity in preclinical models

Slide 19: ADU-S100: Encouraging Preclinical Data
ADU-S100: Encouraging Preclinical Data Activity in B16 Melanoma Tumor Model Significantly Better than TLR Ligands Groups: (N=8) Proprietary ADU-S100 versus TLR Ligands Proprietary ADU-S100 versus Naturally Occurring CDN Injections P<.05 Groups: (N=8) Injections P<.05

Slide 20: ADU-S100: Protective Immunity in Preclinical Model
ADU-S100: Protective Immunity in Preclinical Model Immunity in Lung Metastases Following IT Injection of Primary Tumor B16 subcutaneous injection in the flank (Day 0) followed by IV injection (Day 7) ADU-S100 IT treatment course (Days 14, 17, 21) on primary flank tumor * * * Groups: (N=8) B16 Tumor

Slide 21: ADU-S100/MIW815: First-in-Human Phase 1 Trial
STING ADU-S100/MIW815: First-in-Human Phase 1 Trial in Solid Tumors and Lymphomas Two-part study to assess the safety/tolerability in patients with cutaneously accessible, treatment-refractory primary or metastatic solid tumors or lymphomas (e.g. breast, melanoma, squamous cell carcinoma of the head

Slide 22: B-Select Monoclonal Antibodies
B-Select Monoclonal Antibodies

Slide 23: B-select Monoclonal Antibodies
B-select Monoclonal Antibodies First- or Best-in-Class Immune Modulating Agonist and Antagonist mAbs Proprietary technology probes the entire B-cell response yielding high-affinity antibody candidates targeting unprecedented functional epitopes (e.g. CD27 agonist)

Slide 24: B-Select Platform: Monoclonal Antibody Discovery and Development
B-Select Platform: Monoclonal Antibody Discovery and Development Proven track record of successful antibody development Proprietary ultra-selective B-cell panning method coupled with rigorous functional screening Earlier iteration of technology at Organon led to discovery of pembrolizumab Technology

Slide 25: Anti-APRIL: a First-in-Class Antagonist Antibody
Anti-APRIL: a First-in-Class Antagonist Antibody Blocking APRIL Inhibits Tumor Growth, Drug Resistance & Immune Suppression in Multiple Myeloma (MM) APRIL: A Proliferation Inducing Ligand Soluble factor that binds to BCMA and TACI receptors and induces signaling BCMA is expressed at very high levels

Slide 26: Anti-CD27 Agonist
Anti-CD27 Agonist Anti-CD27 agonist induced T cell-mediated anti-cancer response in pre-clinical studies In combination with PD1, complete tumor eradication was achieved Aduro’s antibody distinctly targets functional epitope on CD27 Leads to potent activation of the CD27 co-stimulatory pathway World

Slide 27: Business Overview
Business Overview ADUR ar BIOTEC

Slide 28: Program Collaborations and Terms
Program Collaboration Indication Terms Commercial LADD Programs CRS-207 Aduro owned Multiple - - ADU-741 Prostate $365M (upfront & potential milestones); Global license Tiered mid single-digit to low teens royalties ADU-214 Lung $817M (upfront & potential milestones); Global license Tiered high sing

Slide 29: 3Q16 Financials and Patent Position
3Q16 Financials and Patent Position Cash & cash equivalents as of 9/30/2016 $387.1 M Operating expenses for third quarter 2016 $27.7 M Shares outstanding as of 10/31/2016 67.2 M Strong Financial Position Extensive Patent Portfolio Global Rights (inclusive of inlicensed patents) >100 issued compositi

Slide 30: Upcoming Milestones
Upcoming Milestones Significant Upcoming Catalysts Expected H1 2017 H2 2017 H1 2018 CRS-207 + αPD-1 Mesothelioma Phase 2 initiation CRS-207 + αPD-1 Gastric Phase 1 initiation pLADD Gastro-intestinal Phase 1 initiation ADU-S100 Multiple tumors Phase 1 monotherapy data ADU-S100 + αPD-1 Multiple tumors

Slide 31: Aduro Biotech
ADURO: BIOTECH.’
Source: SEC EDGAR · 8-K filed Jan 9, 2017
More decks from Aduro Biotech Inc
Chinook Therapeutics — Technical Presentation (June 2023)6 slides · Jun 12, 2023
Merger or Acquisition (June 2020)14 slides · Jun 2, 2020
Jefferies Virtual Healthcare Conference 202018 slides · Jun 2, 2020
Merger or Acquisition (June 2020)16 slides · Jun 2, 2020
Investor Presentation (January 2020)40 slides · Jan 13, 2020
Investor Presentation (January 2019)30 slides · Jan 7, 2019